Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Viridian Therapeutics, Inc.\DE

NASDAQ: VRDN · Life Sciences · 4 alerts · CIK 1590750

Share price
$29.80Close, Nov 16
Market cap
$3.38B
Shares outstanding
113.56MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Viridian Therapeutics, Inc.\DE filings on SEC EDGAR ↗

7:33 AM ET 8-K
Clinical Trial Data

Viridian Therapeutics, Inc.\DE Clinical Trial Data

Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended FcRn inhibitor, which demonstrated a 74% peak reduction in IgG and a half-life 5-6 times longer than first-generation fragments. The data supports a potential best-in-class every-eight-week subcutaneous dosing regimen, and the company plans to initiate a pivotal trial in myasthenia gravis in mid-2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.